Found: 34
Select item for more details and to access through your institution.
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 185, n. 3, p. 697, doi. 10.1007/s10549-020-05981-z
- By:
- Publication type:
- Article
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 2, p. 351, doi. 10.1007/s10549-018-4767-1
- By:
- Publication type:
- Article
A Comparative Analysis on the Efficacy and Safety of Intaxel® and Taxol® in Advanced Metastatic Breast Cancer.
- Published in:
- Journal of Clinical & Diagnostic Research, 2013, v. 7, n. 6, p. 1120, doi. 10.7860/JCDR/2013/4742.3027
- By:
- Publication type:
- Article
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2017, v. 24, n. 2, p. 398, doi. 10.1245/s10434-016-5571-y
- By:
- Publication type:
- Article
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2008, v. 15, n. 11, p. 3227, doi. 10.1245/s10434-008-0129-2
- By:
- Publication type:
- Article
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 5, p. 1217, doi. 10.1007/s00277-019-03639-5
- By:
- Publication type:
- Article
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
- Published in:
- Wiener Klinische Wochenschrift, 2013, v. 125, n. 15/16, p. 439, doi. 10.1007/s00508-013-0385-4
- By:
- Publication type:
- Article
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 2, p. 121, doi. 10.1 093/i nci/djm287
- By:
- Publication type:
- Article
Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 4, p. 771, doi. 10.1111/bcp.14178
- By:
- Publication type:
- Article
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 681, doi. 10.1007/s10637-010-9538-8
- By:
- Publication type:
- Article
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1021, doi. 10.1007/s10637-010-9392-8
- By:
- Publication type:
- Article
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 158, n. 2, p. 323, doi. 10.1007/s10549-016-3863-3
- By:
- Publication type:
- Article
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 17, p. 6234, doi. 10.1002/cam4.3227
- By:
- Publication type:
- Article
An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 5, p. 1660, doi. 10.1002/cam4.1388
- By:
- Publication type:
- Article
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
- Published in:
- Pathology & Oncology Research, 2018, v. 24, n. 2, p. 237, doi. 10.1007/s12253-017-0238-y
- By:
- Publication type:
- Article
Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia.
- Published in:
- Pathology & Oncology Research, 2013, v. 19, n. 1, p. 119, doi. 10.1007/s12253-012-9551-7
- By:
- Publication type:
- Article
Significance of Histomorphology of Early Triple-Negative Breast Cancer.
- Published in:
- Pathology & Oncology Research, 2012, v. 18, n. 4, p. 823, doi. 10.1007/s12253-012-9510-3
- By:
- Publication type:
- Article
Inflammatory Breast Cancer-Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response.
- Published in:
- Pathology & Oncology Research, 2011, v. 17, n. 3, p. 541, doi. 10.1007/s12253-010-9344-9
- By:
- Publication type:
- Article
Az elmúlt évtizedek jeges árvizeinek tapasztalatai és azok alkalmazása.
- Published in:
- Belügyi Szemle / Academic Journal of Internal Affairs, 2022, v. 70, n. 11, p. 2347, doi. 10.38146/BSZ.2022.11.39
- By:
- Publication type:
- Article
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 5, p. 887, doi. 10.1007/s00280-021-04338-7
- By:
- Publication type:
- Article
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Endocrine disrupting chemicals in Hungarian canned foods.
- Published in:
- Environmental Health & Preventive Medicine, 2002, v. 6, n. 4, p. 273, doi. 10.1007/BF02897982
- By:
- Publication type:
- Article
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 348, doi. 10.1634/theoncologist.2014-0021
- By:
- Publication type:
- Article
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 346, doi. 10.1634/theoncologist.2014-0022
- By:
- Publication type:
- Article
Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.
- Published in:
- Oncologist, 2013, v. 18, n. 2, p. 134, doi. 10.1634/theoncologist.2012-0342
- By:
- Publication type:
- Article
Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 5, p. 700, doi. 10.1002/cncr.33318
- By:
- Publication type:
- Article
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article